LeMaitre Vascular Inc (NASDAQ:LMAT) insider Trent G. Kamke sold 15,780 shares of LeMaitre Vascular stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $30.28, for a total value of $477,818.40. Following the completion of the transaction, the insider now owns 31,341 shares in the company, valued at approximately $949,005.48. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of LeMaitre Vascular Inc (NASDAQ:LMAT) traded down 0.79% on Friday, reaching $30.21. The company’s stock had a trading volume of 48,428 shares. The stock has a 50 day moving average of $28.49 and a 200-day moving average of $24.82. The firm has a market cap of $568.22 million, a price-to-earnings ratio of 50.43 and a beta of 0.63. LeMaitre Vascular Inc has a 12 month low of $13.52 and a 12 month high of $33.22.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, May 4th. The medical instruments supplier reported $0.16 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.03. LeMaitre Vascular had a net margin of 12.19% and a return on equity of 12.83%. The business had revenue of $24.10 million during the quarter, compared to analyst estimates of $23.48 million. LeMaitre Vascular’s revenue for the quarter was up 18.7% compared to the same quarter last year. On average, analysts anticipate that LeMaitre Vascular Inc will post $0.70 EPS for the current year.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Wednesday, May 24th will be issued a $0.055 dividend. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $0.22 annualized dividend and a yield of 0.73%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 32.73%.

TRADEMARK VIOLATION NOTICE: “LeMaitre Vascular Inc (LMAT) Insider Trent G. Kamke Sells 15,780 Shares” was published by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/05/26/lemaitre-vascular-inc-lmat-insider-trent-g-kamke-sells-15780-shares.html.

Hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its stake in shares of LeMaitre Vascular by 38.8% in the first quarter. Goldman Sachs Group Inc. now owns 18,966 shares of the medical instruments supplier’s stock valued at $467,000 after buying an additional 5,299 shares during the period. Grandeur Peak Global Advisors LLC raised its stake in shares of LeMaitre Vascular by 7.9% in the first quarter. Grandeur Peak Global Advisors LLC now owns 168,062 shares of the medical instruments supplier’s stock valued at $4,139,000 after buying an additional 12,235 shares during the period. AQR Capital Management LLC raised its stake in shares of LeMaitre Vascular by 35.4% in the first quarter. AQR Capital Management LLC now owns 219,888 shares of the medical instruments supplier’s stock valued at $5,416,000 after buying an additional 57,525 shares during the period. Bank of America Corp DE raised its stake in shares of LeMaitre Vascular by 0.3% in the first quarter. Bank of America Corp DE now owns 193,651 shares of the medical instruments supplier’s stock valued at $4,770,000 after buying an additional 536 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of LeMaitre Vascular by 53.9% in the first quarter. Renaissance Technologies LLC now owns 183,300 shares of the medical instruments supplier’s stock valued at $4,515,000 after buying an additional 64,200 shares during the period. Institutional investors and hedge funds own 61.80% of the company’s stock.

Several equities analysts have recently issued reports on the company. Stifel Nicolaus lifted their price target on LeMaitre Vascular from $25.00 to $29.00 and gave the company a “buy” rating in a research note on Friday, April 28th. Canaccord Genuity reissued a “buy” rating and set a $28.00 price objective on shares of LeMaitre Vascular in a report on Thursday, April 27th. Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a report on Friday, April 28th. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 22nd. Finally, First Analysis initiated coverage on LeMaitre Vascular in a report on Tuesday, March 21st. They set an “overweight” rating and a $29.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. LeMaitre Vascular presently has an average rating of “Buy” and an average target price of $26.43.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

12 Month Chart for NASDAQ:LMAT

Receive News & Ratings for LeMaitre Vascular Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc and related companies with MarketBeat.com's FREE daily email newsletter.